OBJECTIVES: We determined the relationship of smoking status on APOC3 -482C>T polymorphism and apolipoprotein C-III (apoC-III) concentrations and the latter two parameters' influence on risk of diabetes and coronary heart disease (CHD). DESIGN AND METHODS: Prediction of incident cases was assessed at 5.5years' follow-up in unselected 519 individuals of a general population genotyped for -482C>T polymorphism. RESULTS: Female sex and current smoking were significantly associated with low circulating apoC-III in subjects without (p≤0.033) than with abdominal obesity (p=0.053) or than insulin resistant -482TT homozygotes (p=0.034) who had 20-30% higher serum apoC-III. Multi-adjusted serum apoC-III was log-linearly associated with fasting triglycerides. ApoC-III levels determined the development of diabetes [RR 1.56 (95%CI 1.21; 2.01)] and CHD [RR 1.38 (1.10; 1.72) for an increment of 14%], after adjustment for confounders. CONCLUSION: APOC3 -482TT genotype is associated with high apoC-III concentrations only in the presence of abdominal obesity or insulin resistance, but not in current smokers who remain lean or insulin-sensitive. Rather than APOC3 -482C>T polymorphism, circulating apoC-III determines cardiometabolic risk.
OBJECTIVES: We determined the relationship of smoking status on APOC3 -482C>T polymorphism and apolipoprotein C-III (apoC-III) concentrations and the latter two parameters' influence on risk of diabetes and coronary heart disease (CHD). DESIGN AND METHODS: Prediction of incident cases was assessed at 5.5years' follow-up in unselected 519 individuals of a general population genotyped for -482C>T polymorphism. RESULTS: Female sex and current smoking were significantly associated with low circulating apoC-III in subjects without (p≤0.033) than with abdominal obesity (p=0.053) or than insulin resistant -482TT homozygotes (p=0.034) who had 20-30% higher serum apoC-III. Multi-adjusted serum apoC-III was log-linearly associated with fasting triglycerides. ApoC-III levels determined the development of diabetes [RR 1.56 (95%CI 1.21; 2.01)] and CHD [RR 1.38 (1.10; 1.72) for an increment of 14%], after adjustment for confounders. CONCLUSION:APOC3 -482TT genotype is associated with high apoC-III concentrations only in the presence of abdominal obesity or insulin resistance, but not in current smokers who remain lean or insulin-sensitive. Rather than APOC3 -482C>T polymorphism, circulating apoC-III determines cardiometabolic risk.
Authors: Luiz Sérgio F Carvalho; Isabela M Benseñor; Ana C C Nogueira; Bruce B Duncan; Maria I Schmidt; Michael J Blaha; Peter P Toth; Steven R Jones; Raul D Santos; Paulo A Lotufo; Andrei C Sposito Journal: Diabetologia Date: 2020-11-07 Impact factor: 10.122
Authors: Bahareh Rasouli; Valdemar Grill; Kristian Midthjell; Anders Ahlbom; Tomas Andersson; Sofia Carlsson Journal: Diabetes Care Date: 2012-11-19 Impact factor: 19.112
Authors: Peitao Wu; Denis Rybin; Lawrence F Bielak; Mary F Feitosa; Nora Franceschini; Yize Li; Yingchang Lu; Jonathan Marten; Solomon K Musani; Raymond Noordam; Sridharan Raghavan; Lynda M Rose; Karen Schwander; Albert V Smith; Salman M Tajuddin; Dina Vojinovic; Najaf Amin; Donna K Arnett; Erwin P Bottinger; Ayse Demirkan; Jose C Florez; Mohsen Ghanbari; Tamara B Harris; Lenore J Launer; Jingmin Liu; Jun Liu; Dennis O Mook-Kanamori; Alison D Murray; Mike A Nalls; Patricia A Peyser; André G Uitterlinden; Trudy Voortman; Claude Bouchard; Daniel Chasman; Adolfo Correa; Renée de Mutsert; Michele K Evans; Vilmundur Gudnason; Caroline Hayward; Linda Kao; Sharon L R Kardia; Charles Kooperberg; Ruth J F Loos; Michael M Province; Tuomo Rankinen; Susan Redline; Paul M Ridker; Jerome I Rotter; David Siscovick; Blair H Smith; Cornelia van Duijn; Alan B Zonderman; D C Rao; James G Wilson; Josée Dupuis; James B Meigs; Ching-Ti Liu; Jason L Vassy Journal: PLoS One Date: 2020-05-07 Impact factor: 3.752